Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1041-1050 of 3380 for cancer

Edit search filters
  1. Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

    Rochester, MN, Jacksonville, FL

  2. Alisertib in Treating Young Patients with Recurrent or Refractory Solid Tumors or Leukemia

  3. Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

    Scottsdale/Phoenix, AZ, Rochester, MN

  4. A Study Evaluating AMG 424 in Subjects With Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

    Rochester, MN, Scottsdale/Phoenix, AZ

  6. Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment

    Rochester, MN

  7. A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination with Crizotinib

    Scottsdale/Phoenix, AZ, Rochester, MN

  8. Safety Study of VAL-083 in Patients with Recurrent Malignant Glioma

    Rochester, MN

  9. Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

    Rochester, MN

  10. A Study to Evaluate Infigratinib to Treat Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)

    Jacksonville, FL

.

Mayo Clinic Footer